SHR-4375 for Solid Tumors
A Study of SHR-4375 in Subjects With Solid Tumors
Recruiting
Phase 1
Phase 2
Interventional Study
Solid Tumors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 208 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
Who this trial is looking for
This trial is looking for people with solid tumors who have not responded to standard treatments. Participants will receive an injection of SHR-4375 and help researchers learn about its safety and effectiveness.
Are You a Good Fit for This Trial?
You may be able to join if
- I have signed the consent form to join this study.
- I have a measurable disease.
- I have an ECOG performance status of 0 or 1.
- I expect to live for at least 12 weeks.
- I have advanced solid tumors that have not responded to standard therapy, or I cannot take standard therapy, or I do not want standard therapy.
You may not be able to join if
- I have untreated or active central nervous system metastases.
- I have an active autoimmune disease or a history of autoimmune disease.
- I have active hepatitis B or hepatitis C.
- I have had severe infections before starting the study treatment.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. The subjects voluntarily joined the study and signed the ICF.
2. Measurable disease, as defined by RECIST v1.1.
3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Subjects with cytologically or histologically confirm…
Contacts